Document is current
Any future updates will be listed below
-
Authors
Morita, Midori
Tsunashima, Ryo
Yoshinami, Tetsuhiro
Ishida, Masaki
Iwasaku, Masahiro
Kitano, Sae
Kato, Chikage
Sakaguchi, Koichi
Takayama, Koichi
Naoi, Yasuto https://orcid.org/0000-0002-6090-0137
- License Information
-
More Information
Article History
Received: 15 August 2024
Accepted: 21 November 2024
First Online: 4 December 2024
Declarations
:
: Koichi Takayama received grants from Chugai Pharmaceutical and Ono Pharmaceutical, and personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Eli Lilly, Boehringer Ingelheim, and Daiichi Sankyo. Yasuto Naoi has received research funding from Sysmex, ONO, Daiichi-Sankyo and AstraZeneca, and honoraria from AstraZeneca, Pfizer, Eli Lilly, ONO, Daiichi-Sankyo and Chugai outside the submitted work; he holds joint patents with Sysmex including Curebest™ 95GC Breast (JP.5725274.B2). The other authors declare that there are no conflicts of interest.
: Approval of the research protocol by the Ethics Review Committee of Kyoto Prefectural University of Medicine (ERB-C-2860) and by the review board of C-CAT (CDU2023-025N).
: Not applicable.
